Shield Therapeutics (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news
20/20 vision For fighter pilots, it is a minimum requirement. But having 20/20 ‘visual acuity’ (correct term) does not necessarily mean you have perfect vision (as convention assumes); instead, it
Inter alia, we reviewed social infrastructure investment companies in our note “Secure income” REITs – Safe harbour available, published on 22 March 2019. In this note, we consider how RM
Real Estate Credit Investments (LON:RECI) pays investors a high (7.1%) dividend yield, covered by predictable income streams generated by an increasingly diversified portfolio of real-estate-backed debt. Its credit record has
Why invest Positives Strategy: To invest in a portfolio of unquoted media companies that will generate meaningful IP. Issues Time to invest: The target time to invest of 15 months is longer
Tis rare that a company reports on the same day as a general election. Okay, Titon Holdings (LON:TON) gestation was the longer ‒ but the conclusions are the same. “It’s
B-North is raising capital ahead of getting its banking licence (due spring 2020). It will then attack the huge, profitable and poorly-served SME lending market. B-North combines i) state-of-the-art technology
The goal of Advanced Oncotherapy (LON:AVO) is to deliver an affordable and more effective proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In
Palace Capital (LON:PCA) 1H’20 results were announced on 19 November. Seventeen lease events have been completed. Impressively, these were 25% above passing rent and 3% above ERV (i.e. previous estimated
Artificial Solutions (ASAI) is a market leader in the conversational artificial intelligence (AI) segment. Its customers include some of the world’s largest enterprises across market sectors, while partners include many
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
